Compare Amphastar Pharmaceuticals Inc (AMPH) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Linde PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Linde PLC trades at $531.24 (market cap $244.95B). The key difference: Linde PLC is far larger — about 296.5× Amphastar Pharmaceuticals Inc's market cap, and Linde PLC pays a 1.21% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LIN | |
|---|---|---|
Market Cap | $826.08M | $244.95B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $546.64 |
52-Week Low | $16.87 | $389.38 |
Enterprise Value | $1.22B | $267.30B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Linde PLC (LIN) trades at $529.79, up 0.8% today, with strong analyst support (24 buy, 4 hold) and a consensus price target of $560. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust fundamentals including a 20.44% net margin and 18.49% ROE. Technical indicators are bullish overall, with the current price near resistance at $529.
Outlook remains positive due to steady revenue growth, high profitability, and shareholder returns via dividends. Risks include elevated valuation multiples (P/E 35.13) and rising debt-to-asset ratio. The stock offers a balanced opportunity for growth investors, supported by strong institutional sentiment and operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
